烟雾吸入性急性肺损伤药物治疗的研究进展  

Progress in pharmacotherapy of smoke inhalation-induced acute lung injury

作　　者：纵加强 韩志海 Zong Jiaqiang;Han Zhihai(The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China;Department of Pulmonary and Critical Care Medicine,the Sixth Medical Center of Chinese PLA General Hospital,Beijing 100048,China)

机构地区：[1]南方医科大学第二临床医学院,广州510515 [2]中国人民解放军总医院第六医学中心呼吸与危重症医学科,北京100048

出　　处：《国际呼吸杂志》2021年第6期459-463,共5页International Journal of Respiration

基　　金：军队后勤科研计划重点项目(BHJ16J011)。

摘　　要：烟雾吸入性急性肺损伤是火灾中伤员死亡的独立危险因素及死亡的主要原因。烟雾中有毒、有害化学气体和微粒引起的吸入性肺损伤是火灾后住院患者伤残的重要原因。近十年来,烟雾吸入性急性肺损伤相关的急救药物有了显著进展。Smoke inhalation-induced acute lung injury(SI-ALI)is an independent risk factor of death for burn patients in fires,which is also the main cause of death.SI-ALI,caused by toxic and harmful chemical gases and particulates,is an important cause of disability for hospitalized patients after fire hazard.And over the last decade,the life-saving medicines for SI-ALI have made significant progress.

关 键 词：烟雾吸入损伤 药物疗法 研究进展 

分 类 号：R563[医药卫生—呼吸系统]